{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:09:59Z","timestamp":1792976999376,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,17]]},"DOI":"10.7759\/cureus.92549","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T16:42:57Z","timestamp":1758127377000},"source":"Crossref","is-referenced-by-count":7,"title":["Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Acute Myeloid Leukemia: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Alaa Babiker","family":"Mohamed Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehab A","family":"Elagab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eilaf Abuelgasim","family":"Abdalla Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada Eltigani","family":"Hassan Mahgoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima Suliman","family":"Dawod Faky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada Abdelrahman","family":"Shamina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagla","family":"Subahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-022-01021-8","article-title":"Pathogenic mechanisms in acute myeloid leukemia","volume":"23","author":"Chakraborty S","year":"2022","unstructured":"Chakraborty S, Park CY. Pathogenic mechanisms in acute myeloid leukemia. Curr Treat Options Oncol. 2022, 23:1522-34. 10.1007\/s11864-022-01021-8","journal-title":"Curr Treat Options Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001920","article-title":"American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults","volume":"4","author":"Sekeres MA","year":"2020","unstructured":"Sekeres MA, Guyatt G, Abel G, et al.. American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. Blood Adv. 2020, 4:3528-49. 10.1182\/bloodadvances.2020001920","journal-title":"Blood Adv"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04375-x","article-title":"Impact of age, functional status, and comorbidities on quality of life and outcomes in elderly patients with AML","volume":"100","author":"Laribi K","year":"2021","unstructured":"Laribi K, Sobh M, Ghez D, Baugier de Materre A. Impact of age, functional status, and comorbidities on quality of life and outcomes in elderly patients with AML. Ann Hematol. 2021, 100:1359-76. 10.1007\/s00277-020-04375-x","journal-title":"Ann Hematol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.659595","article-title":"Allogeneic stem cell transplantation for acute myeloid leukemia: who, when, and how?","volume":"12","author":"Loke J","year":"2021","unstructured":"Loke J, Buka R, Craddock C. Allogeneic stem cell transplantation for acute myeloid leukemia: who, when, and how?. Front Immunol. 2021, 12:659595. 10.3389\/fimmu.2021.659595","journal-title":"Front Immunol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241915019","article-title":"Novel approaches to treatment of acute myeloid leukemia relapse post allogeneic stem cell transplantation","volume":"24","author":"Liberatore C","year":"2023","unstructured":"Liberatore C, Di Ianni M. Novel approaches to treatment of acute myeloid leukemia relapse post allogeneic stem cell transplantation. Int J Mol Sci. 2023, 24:15019. 10.3390\/ijms241915019","journal-title":"Int J Mol Sci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0356-4","article-title":"Dissecting the biology of allogeneic HSCT to enhance the GvT effect whilst minimizing GvHD","volume":"17","author":"Blazar BR","year":"2020","unstructured":"Blazar BR, Hill GR, Murphy WJ. Dissecting the biology of allogeneic HSCT to enhance the GvT effect whilst minimizing GvHD. Nat Rev Clin Oncol. 2020, 17:475-92. 10.1038\/s41571-020-0356-4","journal-title":"Nat Rev Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.21926\/obm.transplant.2501241","article-title":"Allogeneic stem cell transplantation: current status and future directions","volume":"9","author":"Kumar A","year":"2025","unstructured":"Kumar A, Israr J. Allogeneic stem cell transplantation: current status and future directions. OBM Transplant. 2025, 9:1-15. 10.21926\/obm.transplant.2501241","journal-title":"OBM Transplant"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2025.2547866","article-title":"Therapeutic options for relapsed acute myeloid leukemia after hematopoietic stem cell transplantation","volume":"4","author":"Yolcu A","year":"2025","unstructured":"Yolcu A, Aladag Karakulak E, Goker H. Therapeutic options for relapsed acute myeloid leukemia after hematopoietic stem cell transplantation. Expert Rev Hematol. 2025, 4:16-8. 10.1080\/17474086.2025.2547866","journal-title":"Expert Rev Hematol"},{"key":"ref9","article-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","volume":"9","author":"GA Wells","year":"2000","unstructured":"GA Wells, B Shea, D O'Connell, J Peterson, V Welch, M Losos, P Tugwell. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. OHRI. 2000, 9:26-8.","journal-title":"OHRI"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-025-02560-y","article-title":"Superior outcomes of haploidentical hematopoietic cell transplantation over chemotherapy in AML patients 55 years or older","volume":"60","author":"Li L","year":"2025","unstructured":"Li L, Zhu L, Xiong M, et al.. Superior outcomes of haploidentical hematopoietic cell transplantation over chemotherapy in AML patients 55 years or older. Bone Marrow Transplant. 2025, 60:773-8. 10.1038\/s41409-025-02560-y","journal-title":"Bone Marrow Transplant"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-025-02516-2","article-title":"Relationship between age, conditioning intensity, and outcome after allografting in adults age \u226560 years with AML","volume":"60","author":"Vo PT","year":"2025","unstructured":"Vo PT, Sandmaier BM, Othus M, et al.. Relationship between age, conditioning intensity, and outcome after allografting in adults age \u226560 years with AML. Bone Marrow Transplant. 2025, 60:482-90. 10.1038\/s41409-025-02516-2","journal-title":"Bone Marrow Transplant"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.285879","article-title":"Hematopoietic cell transplantation for older acute myeloid leukemia patients in first complete remission: results of a randomized phase III study","volume":"110","author":"Niederwieser D","year":"2025","unstructured":"Niederwieser D, Hasenclever D, Berdel WE, et al.. Hematopoietic cell transplantation for older acute myeloid leukemia patients in first complete remission: results of a randomized phase III study. Haematologica. 2025, 110:68-77. 10.3324\/haematol.2024.285879","journal-title":"Haematologica"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-024-02275-6","article-title":"Allogeneic hematopoietic cell transplantation for older patients with AML with active disease. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)","volume":"59","author":"Maffini E","year":"2024","unstructured":"Maffini E, Labopin M, Kr\u00f6ger N, et al.. Allogeneic hematopoietic cell transplantation for older patients with AML with active disease. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2024, 59:983-90. 10.1038\/s41409-024-02275-6","journal-title":"Bone Marrow Transplant"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.282729","article-title":"Allogeneic transplantation in acute myelogenous leukemia: a comprehensive single institution's experience","volume":"108","author":"Socie G","year":"2023","unstructured":"Socie G, Galimard JE, Raffoux E, et al.. Allogeneic transplantation in acute myelogenous leukemia: a comprehensive single institution's experience. Haematologica. 2023, 108:2369-79. 10.3324\/haematol.2023.282729","journal-title":"Haematologica"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-023-02027-y","article-title":"Allogeneic hematopoietic cell transplantation for patients with AML aged 70 years or older in first remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)","volume":"58","author":"Maffini E","year":"2023","unstructured":"Maffini E, Ngoya M, Galimard JE, et al.. Allogeneic hematopoietic cell transplantation for patients with AML aged 70 years or older in first remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2023, 58:1033-41. 10.1038\/s41409-023-02027-y","journal-title":"Bone Marrow Transplant"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.09.021","article-title":"Allogeneic hematopoietic cell transplantation for patients with relapsed acute promyelocytic leukemia","volume":"28","author":"Yanada M","year":"2022","unstructured":"Yanada M, Matsuda K, Ishii H, et al.. Allogeneic hematopoietic cell transplantation for patients with relapsed acute promyelocytic leukemia. Transplant Cell Ther. 2022, 28:847.e1-8. 10.1016\/j.jtct.2022.09.021","journal-title":"Transplant Cell Ther"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.5045\/br.2022.2022060","article-title":"Treatment for relapsed acute promyelocytic leukemia: what is the best post-remission treatment?","volume":"57","author":"Min GJ","year":"2022","unstructured":"Min GJ, Cho BS, Park SS, et al.. Treatment for relapsed acute promyelocytic leukemia: what is the best post-remission treatment?. Blood Res. 2022, 57:197-206. 10.5045\/br.2022.2022060","journal-title":"Blood Res"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-01162-0","article-title":"Hematopoietic stem cell transplantation for adults with relapsed acute promyelocytic leukemia in second complete remission","volume":"56","author":"Sanz J","year":"2021","unstructured":"Sanz J, Labopin M, Sanz MA, et al.. Hematopoietic stem cell transplantation for adults with relapsed acute promyelocytic leukemia in second complete remission. Bone Marrow Transplant. 2021, 56:1272-80. 10.1038\/s41409-020-01162-0","journal-title":"Bone Marrow Transplant"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2883","article-title":"A phase II study evaluating the role of bortezomib in the management of relapsed acute promyelocytic leukemia treated upfront with arsenic trioxide","volume":"9","author":"Kulkarni U","year":"2020","unstructured":"Kulkarni U, Ganesan S, Alex AA, et al.. A phase II study evaluating the role of bortezomib in the management of relapsed acute promyelocytic leukemia treated upfront with arsenic trioxide. Cancer Med. 2020, 9:2603-10. 10.1002\/cam4.2883","journal-title":"Cancer Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation.V2012.1.230.3798312","article-title":"Haploidentical transplantation for hematologic malignancies: where do we stand?","volume":"5","author":"Fuchs EJ","year":"2012","unstructured":"Fuchs EJ. Haploidentical transplantation for hematologic malignancies: where do we stand?. Hematology. 2012, 5:230-6. 10.1182\/asheducation.V2012.1.230.3798312","journal-title":"Hematology"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003662","article-title":"Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?","volume":"135","author":"Ciurea SO","year":"2020","unstructured":"Ciurea SO, Kongtim P, Varma A, et al.. Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?. Blood. 2020, 135:449-52. 10.1182\/blood.2019003662","journal-title":"Blood"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005524","article-title":"A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia","volume":"137","author":"Fenwarth L","year":"2021","unstructured":"Fenwarth L, Thomas X, de Botton S, et al.. A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia. Blood. 2021, 137:524-32. 10.1182\/blood.2020005524","journal-title":"Blood"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.08.009","article-title":"Choosing between older matched sibling donor and younger matched unrelated donor in allogeneic hematopoietic cell transplantation: comparison of clinical outcomes in acute myeloid leukemia and myelodysplastic syndrome","volume":"29","author":"Pereira MP","year":"2023","unstructured":"Pereira MP, Remberger M, Chen C, et al.. Choosing between older matched sibling donor and younger matched unrelated donor in allogeneic hematopoietic cell transplantation: comparison of clinical outcomes in acute myeloid leukemia and myelodysplastic syndrome. Transplant Cell Ther. 2023, 29:697.e1-697.e10. 10.1016\/j.jtct.2023.08.009","journal-title":"Transplant Cell Ther"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-023-01961-1","article-title":"Impact of disease burden on clinical outcomes of AML patients receiving allogeneic hematopoietic cell transplantation: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"58","author":"Abou Dalle I","year":"2023","unstructured":"Abou Dalle I, Labopin M, Kr\u00f6ger N, et al.. Impact of disease burden on clinical outcomes of AML patients receiving allogeneic hematopoietic cell transplantation: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2023, 58:784-90. 10.1038\/s41409-023-01961-1","journal-title":"Bone Marrow Transplant"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10173790","article-title":"The role of allogeneic hematopoietic stem cell transplantation in pediatric leukemia","volume":"10","author":"Algeri M","year":"2021","unstructured":"Algeri M, Merli P, Locatelli F, Pagliara D. The role of allogeneic hematopoietic stem cell transplantation in pediatric leukemia. J Clin Med. 2021, 10:32-4. 10.3390\/jcm10173790","journal-title":"J Clin Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-01-894980","article-title":"Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet","volume":"133","author":"Sanz MA","year":"2019","unstructured":"Sanz MA, Fenaux P, Tallman MS, et al.. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood. 2019, 133:1630-43. 10.1182\/blood-2019-01-894980","journal-title":"Blood"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009010","article-title":"Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia","volume":"7","author":"Lachowiez CA","year":"2023","unstructured":"Lachowiez CA, Long N, Saultz J, et al.. Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia. Blood Adv. 2023, 7:1899-909. 10.1182\/bloodadvances.2022009010","journal-title":"Blood Adv"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.06.019","article-title":"Haploidentical hematopoietic cell transplant with post-transplant cyclophosphamide and peripheral blood stem cell grafts in older adults with acute myeloid leukemia or myelodysplastic syndrome","volume":"23","author":"Slade M","year":"2017","unstructured":"Slade M, DiPersio JF, Westervelt P, Vij R, Schroeder MA, Romee R. Haploidentical hematopoietic cell transplant with post-transplant cyclophosphamide and peripheral blood stem cell grafts in older adults with acute myeloid leukemia or myelodysplastic syndrome. Biol Blood Marrow Transplant. 2017, 23:1736-43. 10.1016\/j.bbmt.2017.06.019","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/409092-outcomes-of-allogeneic-hematopoietic-stem-cell-transplantation-in-adult-acute-myeloid-leukemia-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T16:43:01Z","timestamp":1758127381000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/409092-outcomes-of-allogeneic-hematopoietic-stem-cell-transplantation-in-adult-acute-myeloid-leukemia-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,17]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.92549","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,17]]}}}